MX2016015005A - Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1. - Google Patents
Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1.Info
- Publication number
- MX2016015005A MX2016015005A MX2016015005A MX2016015005A MX2016015005A MX 2016015005 A MX2016015005 A MX 2016015005A MX 2016015005 A MX2016015005 A MX 2016015005A MX 2016015005 A MX2016015005 A MX 2016015005A MX 2016015005 A MX2016015005 A MX 2016015005A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrrolidine
- methods
- pharmaceutical compositions
- dione derivatives
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
- C07D207/408—Radicals containing only hydrogen and carbon atoms attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
La presente invención se refiere al compuesto de la fórmula I (ver Fórmula) o sus enantiómeros, sales, solvatos o profármacos farmacéuticamente aceptables. La invención también se refiere al uso de los compuestos de la fórmula I como inhibidores de lDO1. La invención también se refiere al uso de los compuestos de la fórmula I para el tratamiento y/o la prevención de cáncer y endometriosis. La invención también se refiere a un proceso para preparar los compuestos de la fórmula I.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461996976P | 2014-05-15 | 2014-05-15 | |
EP14168534 | 2014-05-15 | ||
BE2014/0754A BE1021251B1 (fr) | 2014-05-15 | 2014-10-21 | Derives de pyrrolidine-2,5-dione, compositions pharmaceutiques et methodes d'utilisation comme inhibiteurs de ido1 |
PCT/IB2015/053557 WO2015173764A1 (en) | 2014-05-15 | 2015-05-14 | Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016015005A true MX2016015005A (es) | 2017-09-28 |
Family
ID=54479389
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016015005A MX2016015005A (es) | 2014-05-15 | 2015-05-14 | Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1. |
Country Status (20)
Country | Link |
---|---|
US (3) | US9603836B2 (es) |
EP (1) | EP3148531A1 (es) |
JP (1) | JP6231226B2 (es) |
KR (1) | KR101873672B1 (es) |
CN (1) | CN106536480B (es) |
AP (1) | AP2016009527A0 (es) |
AU (1) | AU2015260826B2 (es) |
CA (1) | CA2948842C (es) |
CU (1) | CU20160162A7 (es) |
DO (1) | DOP2016000299A (es) |
EA (1) | EA201650031A1 (es) |
IL (1) | IL248915A0 (es) |
MD (1) | MD20160118A2 (es) |
MX (1) | MX2016015005A (es) |
PE (1) | PE20170247A1 (es) |
SG (1) | SG11201608708WA (es) |
TN (1) | TN2016000501A1 (es) |
TW (1) | TWI567059B (es) |
UY (1) | UY36122A (es) |
WO (1) | WO2015173764A1 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
CN106536480B (zh) | 2014-05-15 | 2019-09-03 | 艾特奥斯治疗公司 | 吡咯烷-2,5-二酮衍生物、药物组合物及用作ido1抑制剂的方法 |
KR102013512B1 (ko) | 2015-03-17 | 2019-08-22 | 화이자 인코포레이티드 | 신규 3-인돌 치환 유도체, 제약 조성물 및 사용 방법 |
TW201705955A (zh) | 2015-05-14 | 2017-02-16 | 輝瑞大藥廠 | 包含吡咯啶-2,5-二酮ido1抑制劑及抗-pd1/抗-pd-l1抗體之組合療法 |
EP3297672B1 (en) | 2015-05-21 | 2021-09-01 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
JP2018527336A (ja) | 2015-08-10 | 2018-09-20 | ファイザー・インク | 3−インドール置換誘導体、医薬組成物、および使用方法 |
JP6820935B2 (ja) | 2016-01-19 | 2021-01-27 | ファイザー・インク | がんワクチン |
WO2017153459A1 (en) | 2016-03-09 | 2017-09-14 | Netherlands Translational Research Center B.V. | Inhibitors of indoleamine 2,3-dioxygenase |
EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR THE DEGRADATION OF TARGET PROTEINS |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
WO2018054365A1 (en) | 2016-09-24 | 2018-03-29 | Beigene, Ltd. | NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES |
US20190365878A1 (en) * | 2016-11-08 | 2019-12-05 | The Johns Hopkins University | Pharmaceutical treatments for preventing or treating pancreatic cancer |
CA3047002A1 (en) | 2017-01-17 | 2018-07-26 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
CA3063359A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
CA3060989A1 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
SG11202000197PA (en) | 2017-07-11 | 2020-02-27 | Pfizer | Immunogenic compositions comprising cea muc1 and tert |
US11267824B2 (en) | 2017-08-17 | 2022-03-08 | Idorsia Pharmaceuticals Ltd | Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase |
US11053230B2 (en) | 2017-09-01 | 2021-07-06 | Netherlands Translational Research Center B.V. | 3-hydroxy-imidazolidin-4-one compounds as inhibitors of indoleamine 2,3-dioxygenase |
JP7066837B2 (ja) | 2017-10-13 | 2022-05-13 | ハープーン セラピューティクス,インク. | B細胞成熟抗原結合タンパク質 |
US20200405696A1 (en) | 2018-01-15 | 2020-12-31 | Idorsia Pharmaceuticals Ltd | Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase |
WO2020018670A1 (en) | 2018-07-17 | 2020-01-23 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
US11376255B2 (en) | 2018-09-11 | 2022-07-05 | iTeos Belgium SA | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
AU2019337974A1 (en) | 2018-09-11 | 2021-04-08 | iTeos Belgium SA | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
BE1026615B1 (fr) | 2018-09-27 | 2020-07-06 | Iteos Therapeutics S A | Combinaison d’un inhibiteur du récepteur a2a et d'un agent anticancéreux |
WO2020069028A1 (en) | 2018-09-25 | 2020-04-02 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
JP2022540146A (ja) | 2019-07-11 | 2022-09-14 | イドーシア ファーマシューティカルズ リミテッド | インドールアミン 2,3-ジオキシゲナーゼ及び/又はトリプトファン 2,3-ジオキシゲナーゼの阻害剤 |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
US20230165863A1 (en) | 2020-04-16 | 2023-06-01 | iTeos Belgium SA | Methods and formulations for administration of thiocarbamate deriviatives a2a inhibitors |
MX2023000197A (es) | 2020-07-07 | 2023-02-22 | BioNTech SE | Arn terapeutico para el cancer positivo para vph. |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
US20240141436A1 (en) | 2021-02-17 | 2024-05-02 | iTeos Belgium SA | Compounds, Compositions and Methods of Treatment Thereof |
EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
JP2024510949A (ja) | 2021-03-05 | 2024-03-12 | ウニヴェルシタット・バーゼル | Ebv関連疾患又は状態の治療用組成物 |
KR20240046323A (ko) | 2021-07-13 | 2024-04-08 | 비온테크 에스이 | 암에 대한 병용 요법에 있어서 cd40 및 cd137에 대한 다중특이 결합제 |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
WO2023170606A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE509731C2 (sv) | 1996-05-14 | 1999-03-01 | Labwell Ab | Metod för palladium-katalyserade organiska reaktioner innefattande ett uppvärmningssteg utfört med mikrovågsenergi |
JP2000095759A (ja) | 1998-07-21 | 2000-04-04 | Takeda Chem Ind Ltd | 三環性化合物、その製造法および剤 |
US6265403B1 (en) | 1999-01-20 | 2001-07-24 | Merck & Co., Inc. | Angiogenesis inhibitors |
WO2003035625A1 (en) | 2001-09-19 | 2003-05-01 | Pharmacia Corporation | Substituted indazole compounds for the treatment of inflammation |
DE60331219D1 (de) | 2002-03-28 | 2010-03-25 | Eisai R&D Man Co Ltd | Azaindole als hemmstoffe von c-jun n-terminalen kinasen |
TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
FR2845996A1 (fr) * | 2002-10-16 | 2004-04-23 | Servier Lab | Nouveaux derives de[3,4-a:3,4-c]carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
CN101265254A (zh) | 2003-03-27 | 2008-09-17 | 兰肯瑙医学研究所 | 新型ido抑制剂及其使用方法 |
FR2862647B1 (fr) | 2003-11-25 | 2008-07-04 | Aventis Pharma Sa | Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant |
GB0328909D0 (en) | 2003-12-12 | 2004-01-14 | Syngenta Participations Ag | Chemical compounds |
GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
CN101941970B (zh) * | 2005-02-09 | 2013-08-21 | 艾科优公司 | 用于治疗癌症的meleimide衍生物、药物组合物以及方法 |
WO2007039580A1 (en) | 2005-10-05 | 2007-04-12 | Nycomed Gmbh | Imidazolyl-substituted benzophenone compounds |
WO2007045622A1 (en) | 2005-10-18 | 2007-04-26 | Nycomed Gmbh | Oxazolo [4 , 5-b] pyridine compounds as nitric oxide synthase inhibitors |
EP1940787A4 (en) | 2005-10-27 | 2009-07-01 | Lankenau Inst Medical Res | NOVEL IDO INHIBITORS AND METHODS OF USE |
US7932284B2 (en) | 2006-01-24 | 2011-04-26 | Eli Lilly And Company | Indole sulfonamide modulators of progesterone receptors |
EP2001480A4 (en) | 2006-03-31 | 2011-06-15 | Abbott Lab | Indazole CONNECTIONS |
EP2591775A1 (en) | 2006-04-05 | 2013-05-15 | Novartis AG | Combinations comprising mtor inhibitors for treating cancer |
GB0624308D0 (en) | 2006-12-05 | 2007-01-17 | Molmed Spa | Combination product |
BRPI0720049A2 (pt) | 2006-12-07 | 2014-01-07 | Novartis Ag | Derivados de piridina utilizados como inibidores de xiap |
NZ578744A (en) | 2007-01-31 | 2012-02-24 | Vertex Pharma | 2-aminopyridine derivatives useful as kinase inhibitors |
WO2008115804A1 (en) | 2007-03-16 | 2008-09-25 | Lankenau Institute For Medical Research | Novel ido inhibitors and methods of use thereof |
WO2009015067A2 (en) | 2007-07-25 | 2009-01-29 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
US7868001B2 (en) | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
EP2227770A4 (en) | 2007-11-30 | 2011-11-09 | Glaxosmithkline Llc | PROLYLHYDROXYLASEINHIBITOREN |
ES2524259T3 (es) | 2008-03-24 | 2014-12-04 | Novartis Ag | Inhibidores de metaloproteinasa de matriz a base de arilsulfonamida |
WO2010008427A1 (en) | 2008-04-11 | 2010-01-21 | Ludwig Institute For Cancer Research Ltd. | Tryptophan catabolism in cancer treatment and diagnosis |
DE102008052943A1 (de) | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | Azaindolderivate |
CN102325753B (zh) | 2008-12-19 | 2014-09-10 | 百时美施贵宝公司 | 用作激酶抑制剂的咔唑甲酰胺化合物 |
CA2752596A1 (en) | 2009-02-17 | 2010-08-26 | Vertex Pharmaceuticals Incorporated | Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase |
WO2010136491A1 (en) | 2009-05-27 | 2010-12-02 | F. Hoffmann-La Roche Ag | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
KR101256018B1 (ko) | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
US9079904B2 (en) * | 2009-09-23 | 2015-07-14 | Medivation Technologies, Inc. | Pyrido[3,4-B]indoles and methods of use |
IN2012DN02679A (es) | 2009-10-12 | 2015-09-04 | Bayer Cropscience Ag | |
ES2749504T3 (es) | 2009-10-13 | 2020-03-20 | Ligand Pharm Inc | Compuestos de moléculas pequeñas miméticos del factor de crecimiento hematopoyético y sus usos |
CN103282034A (zh) | 2010-11-18 | 2013-09-04 | 利亘制药公司 | 造血生长因子模拟物的用途 |
US9321756B2 (en) | 2011-03-22 | 2016-04-26 | Amgen Inc. | Azole compounds as PIM inhibitors |
PL2714677T3 (pl) | 2011-05-23 | 2019-02-28 | Merck Patent Gmbh | Pochodne pirydynowe i pirazynowe |
CA2844799A1 (en) | 2011-08-17 | 2013-02-21 | Amgen Inc. | Heteroaryl sodium channel inhibitors |
US20160263087A1 (en) | 2013-11-08 | 2016-09-15 | Iteos Therapeutics | Novel 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
US9126984B2 (en) | 2013-11-08 | 2015-09-08 | Iteos Therapeutics | 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
CA2939164A1 (en) | 2014-02-12 | 2015-08-20 | Iteos Therapeutics | Novel 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use |
US20150266857A1 (en) | 2014-03-18 | 2015-09-24 | Iteos Therapeutics | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
JP2017507983A (ja) | 2014-03-18 | 2017-03-23 | アイティーオス セラペウティクス | 新規な3−インドール置換誘導体、医薬組成物、および使用方法 |
CN106536480B (zh) | 2014-05-15 | 2019-09-03 | 艾特奥斯治疗公司 | 吡咯烷-2,5-二酮衍生物、药物组合物及用作ido1抑制剂的方法 |
-
2015
- 2015-05-14 CN CN201580024882.8A patent/CN106536480B/zh not_active Expired - Fee Related
- 2015-05-14 WO PCT/IB2015/053557 patent/WO2015173764A1/en active Application Filing
- 2015-05-14 JP JP2016567533A patent/JP6231226B2/ja not_active Expired - Fee Related
- 2015-05-14 PE PE2016002241A patent/PE20170247A1/es not_active Application Discontinuation
- 2015-05-14 EA EA201650031A patent/EA201650031A1/ru unknown
- 2015-05-14 TW TW104115441A patent/TWI567059B/zh active
- 2015-05-14 MD MDA20160118A patent/MD20160118A2/ro not_active Application Discontinuation
- 2015-05-14 SG SG11201608708WA patent/SG11201608708WA/en unknown
- 2015-05-14 TN TN2016000501A patent/TN2016000501A1/en unknown
- 2015-05-14 US US14/711,911 patent/US9603836B2/en active Active
- 2015-05-14 AU AU2015260826A patent/AU2015260826B2/en not_active Ceased
- 2015-05-14 KR KR1020167031517A patent/KR101873672B1/ko active IP Right Grant
- 2015-05-14 CA CA2948842A patent/CA2948842C/en active Active
- 2015-05-14 MX MX2016015005A patent/MX2016015005A/es unknown
- 2015-05-14 EP EP15731680.3A patent/EP3148531A1/en not_active Withdrawn
- 2015-05-14 UY UY0001036122A patent/UY36122A/es not_active Application Discontinuation
-
2016
- 2016-05-14 AP AP2016009527A patent/AP2016009527A0/en unknown
- 2016-10-21 US US15/331,446 patent/US9949951B2/en active Active
- 2016-11-08 CU CUP2016000162A patent/CU20160162A7/es unknown
- 2016-11-13 IL IL248915A patent/IL248915A0/en unknown
- 2016-11-15 DO DO2016000299A patent/DOP2016000299A/es unknown
-
2018
- 2018-03-23 US US15/934,246 patent/US10398679B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN106536480A8 (zh) | 2017-06-30 |
US20180214415A1 (en) | 2018-08-02 |
US9603836B2 (en) | 2017-03-28 |
JP6231226B2 (ja) | 2017-11-15 |
WO2015173764A1 (en) | 2015-11-19 |
EP3148531A1 (en) | 2017-04-05 |
MD20160118A2 (ro) | 2017-04-30 |
CA2948842C (en) | 2019-09-24 |
AU2015260826B2 (en) | 2019-10-24 |
TW201605794A (zh) | 2016-02-16 |
AP2016009527A0 (en) | 2016-10-31 |
CU20160162A7 (es) | 2017-03-03 |
IL248915A0 (en) | 2017-01-31 |
JP2017515850A (ja) | 2017-06-15 |
KR101873672B1 (ko) | 2018-07-02 |
US9949951B2 (en) | 2018-04-24 |
CA2948842A1 (en) | 2015-11-19 |
US10398679B2 (en) | 2019-09-03 |
KR20160146807A (ko) | 2016-12-21 |
DOP2016000299A (es) | 2017-03-15 |
CN106536480A (zh) | 2017-03-22 |
TWI567059B (zh) | 2017-01-21 |
SG11201608708WA (en) | 2016-11-29 |
EA201650031A1 (ru) | 2017-06-30 |
TN2016000501A1 (en) | 2018-04-04 |
US20170035731A1 (en) | 2017-02-09 |
CN106536480B (zh) | 2019-09-03 |
US20150329525A1 (en) | 2015-11-19 |
UY36122A (es) | 2016-01-08 |
PE20170247A1 (es) | 2017-03-29 |
AU2015260826A1 (en) | 2016-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016015005A (es) | Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1. | |
PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
MX2022012317A (es) | Oxisteroles y metodos de uso de los mismos. | |
MX2016017030A (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos. | |
NZ727185A (en) | Phosphatidylinositol 3-kinase inhibitors | |
MX2015012427A (es) | Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer. | |
MX2021014531A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
MX2020011449A (es) | Oxiesteroles y metodos de uso de los mismos. | |
NZ726608A (en) | Phosphatidylinositol 3-kinase inhibitors | |
NZ746825A (en) | Oxysterols and methods of use thereof | |
MX2016010106A (es) | Derivados de quinolona como inhibidores del receptor del factor de crecimiento de fibroblastos. | |
NZ726360A (en) | Phosphatidylinositol 3-kinase inhibitors | |
PH12014502586A1 (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
NZ726638A (en) | Phosphatidylinositol 3-kinase inhibitors | |
MY194116A (en) | Pharmaceutical compounds | |
MX2018001992A (es) | Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa. | |
MX362896B (es) | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cáncer. | |
PH12016501997A1 (en) | Cycloalkyl-linked diheterocycle derivatives | |
MX2017008074A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß). | |
MX2017002544A (es) | Derivados de isoquinolinona utiles en el tratamiento contra el cancer. | |
PH12016502281A1 (en) | Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors | |
MA39993A (fr) | Dérivés de pyrrolidine -2,5-dione, compositions pharmaceutiques et procédés pour une utilisation en tant qu'inhibiteursde de ido1 | |
CR20160532A (es) | Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1 |